Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021

On October 29, 2021 Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that it will release third quarter 2021 results on Wednesday, November 10, 2021, and host a conference call at 8:30 a.m. EST to discuss financial results and recent corporate developments (Press release, Affimed, OCT 29, 2021, View Source [SID1234592197]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference passcode 6166004 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the "Investors" section of company’s website at View Source A replay of the call will be archived on Affimed’s website for 30 days after the call.